科前生物(688526) - 2024 Q3 - 季度财报

Financial Performance - Revenue for the third quarter was RMB 264,996,187.59, a decrease of 10.35% year-over-year[2] - Net profit attributable to shareholders was RMB 107,992,350.87, down 8.68% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 91,050,573.74, a decrease of 19.05% year-over-year[2] - Total operating income for the first three quarters of 2024 was RMB 665,506,663.22, a decrease of 19.57% compared to RMB 827,439,173.94 in the same period of 2023[21] - Net profit attributable to the parent company's shareholders for the first three quarters of 2024 was RMB 260,600,917.75, a decrease of 27.09% compared to RMB 357,428,181.10 in the same period of 2023[22] - Basic earnings per share for the first three quarters of 2024 were RMB 0.56, a decrease of 27.27% compared to RMB 0.77 in the same period of 2023[22] - Total comprehensive income for the first three quarters of 2024 was RMB 252,452,355.32, a decrease of 29.33% compared to RMB 357,180,085.48 in the same period of 2023[22] - Weighted average return on equity (ROE) for the quarter was 2.83%, a decrease of 0.36 percentage points year-over-year[4] R&D Investment - R&D investment for the quarter was RMB 20,793,219.04, accounting for 7.85% of revenue, an increase of 0.85 percentage points year-over-year[4] - R&D investment for the year-to-date was RMB 61,152,604.48, accounting for 9.19% of revenue, an increase of 1.39 percentage points year-over-year[4] - Research and development expenses for the first three quarters of 2024 were RMB 61,152,604.48, a decrease of 5.19% compared to RMB 64,500,664.25 in the same period of 2023[21] - The company invested RMB 1,242,724.02 in the development of a recombinant canine distemper virus live vaccine expressing canine parvovirus VP2 protein[14] - A total of RMB 1,603,240.81 was invested in the clinical trials of a rabies inactivated vaccine (SAD-dOG strain)[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 4,431,964,850.75, a decrease of 5.12% compared to the end of the previous year[4] - The company's total assets as of September 30, 2024, amounted to RMB 4,431,964,850.75, a decrease from RMB 4,671,249,471.01 at the end of 2023[17][18] - Current assets totaled RMB 2,396,570,097.09, down from RMB 2,566,086,573.76 at the end of 2023[17][18] - Non-current assets stood at RMB 2,035,394,753.66, compared to RMB 2,105,162,897.25 at the end of 2023[17][18] - The company's monetary funds decreased to RMB 398,150,650.98 from RMB 581,740,744.51 at the end of 2023[17] - Trade receivables increased slightly to RMB 334,409,367.70 from RMB 331,412,360.97 at the end of 2023[17] - Inventory decreased to RMB 110,569,040.67 from RMB 144,801,907.79 at the end of 2023[18] - Short-term borrowings decreased significantly to RMB 57,038,838.80 from RMB 206,650,359.95 at the end of 2023[18] - Accounts payable decreased to RMB 116,673,632.98 from RMB 132,336,224.11 at the end of 2023[18] - Total liabilities as of the end of Q3 2024 were RMB 573,292,950.74, a decrease of 31.21% compared to RMB 833,592,147.28 at the end of Q3 2023[19] - Contract liabilities as of the end of Q3 2024 were RMB 179,480,006.86, an increase of 13.87% compared to RMB 157,606,070.48 at the end of Q3 2023[19] - Total equity attributable to the parent company's shareholders as of the end of Q3 2024 was RMB 3,857,235,244.36, an increase of 0.56% compared to RMB 3,835,627,197.55 at the end of Q3 2023[20] Cash Flow - Net cash flow from operating activities for the year-to-date was RMB 273,090,876.80, a decrease of 38.72% year-over-year[2] - Net cash flow from operating activities for the first three quarters of 2024 was 273,090,876.80 RMB, a decrease from 445,645,549.29 RMB in the same period of 2023[23] - Cash received from investments in the first three quarters of 2024 was 913,836,754.68 RMB, compared to 875,486,738.26 RMB in the same period of 2023[23] - Net cash flow from investing activities for the first three quarters of 2024 was 28,281,518.30 RMB, an improvement from -185,672,702.13 RMB in the same period of 2023[24] - Cash received from borrowings in the first three quarters of 2024 was 97,000,000.00 RMB, a significant decrease from 260,000,000.00 RMB in the same period of 2023[24] - Net cash flow from financing activities for the first three quarters of 2024 was -465,226,184.63 RMB, compared to -55,061,968.21 RMB in the same period of 2023[24] - The net increase in cash and cash equivalents for the first three quarters of 2024 was -163,865,328.29 RMB, compared to 204,910,878.95 RMB in the same period of 2023[24] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 was 393,503,454.65 RMB, down from 655,612,334.08 RMB at the end of the same period in 2023[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 8,051[10] - The top 10 shareholders hold a significant portion of the company's shares, with Wuhan Huazhong Agricultural University Asset Management Co., Ltd. holding 16.73% (78,004,310 shares) and Chen Huanchun holding 15.20% (70,860,470 shares)[10] Veterinary Drug Development - The company has obtained 49 new veterinary drug registration certificates, including 33 in collaboration with Huazhong Agricultural University, 13 with third parties, and 3 independently[12] - The cumulative investment in the research of the pseudorabies gene-engineered live vaccine for pigs is 11,628,374.53 RMB, with a new veterinary drug registration achieved[13] - The cumulative investment in the research of the infectious bovine rhinotracheitis gene-engineered live vaccine is 13,731,481.72 RMB, currently in the laboratory research phase[13] - The cumulative investment in the research of the Mycoplasma bovis live vaccine (M.bovis HB0801-150 strain) is 10,506,276.05 RMB, with a new veterinary drug registration achieved[13] - The cumulative investment in the research of the porcine delta coronavirus inactivated vaccine (CHNHN-2014 strain) is 8,731,037.38 RMB, with a new veterinary drug registration certificate obtained[13] Sales and Expenses - The company's sales decline was attributed to market conditions and the impact of African swine fever, leading to reduced revenue[7] - Sales expenses for the first three quarters of 2024 were RMB 93,026,235.06, a decrease of 23.03% compared to RMB 120,879,001.48 in the same period of 2023[21] - Financial expenses for the first three quarters of 2024 were RMB -46,009,084.69, a decrease of 5.12% compared to RMB -48,492,906.69 in the same period of 2023[21] - Sales revenue from goods and services received in cash for the first three quarters of 2024 was 636,729,841.36 RMB, compared to 887,405,231.05 RMB in the same period of 2023[23] Non-Recurring Gains and Losses - Non-recurring gains and losses for the quarter amounted to RMB 16,941,777.13, primarily due to government subsidies and financial asset gains[6]